SC
BCAX

Savant Capital’s Bicara Therapeutics BCAX Stock Holding History

Savant Capital’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243K Buy
+8,201
New +$183K ﹤0.01% 1631

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Savant Capital's BCAX Position: Q2 2026 in Review

Savant Capital opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 8,201 shares worth $243K. The stake represents ﹤0.01% of the portfolio and ranks #1631 among its holdings.

172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Savant Capital held 8,201 shares of Bicara Therapeutics worth $243K as of Q2 2026.
  • Bicara Therapeutics was a new Savant Capital position in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1631 holding.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.